The Patent Finder

Sanofi Biotechnology

46 patents currently held · Updated Nov 16, 2026
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 4 name spellings.

0
Ending by 2030
Jan 2032
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Feb 6 to 15, 2027 · next Feb 6
  • 2 fees due Apr 1 to 3, 2027 · next Apr 1
  • 1 fee due May 26, 2027
    The maintenance fee for Methods for Treating Severe Atopic Dermatitis by Administering an IL-4R Inhibitor (US 10,485,844) comes due May 26, 2027. Unpaid by Nov 26, 2027, it lapses early.
  • 1 fee due Jun 3, 2027
    The maintenance fee for Methods for Inhibiting Atherosclerosis by Administering an Inhibitor of PCSK9 (US 10,494,442) comes due Jun 3, 2027. Unpaid by Dec 3, 2027, it lapses early.
  • 1 fee due Sep 19, 2027
    The maintenance fee for Methods of Treating Cancer Pain by Administering a PD-1 Inhibitor (US 11,932,692) comes due Sep 19, 2027. Unpaid by Mar 20, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 6 of the patents on this record were granted since Aug 18, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 12,083,176Human Antibodies to PCSK9 for Use in Methods of Treating Particular Groups of Subjects
In force
 · Low confidence
In forceLow confidence
US 11,246,925Human Antibodies to PCSK9 for Use in Methods of Treating Particular Groups of Subjects
In force
 · Medium confidence
In forceMedium confidence
US 9,561,155Method of Reducing Cholesterol Levels Using a Human ANTI-PCSK9 Antibody
In force
 · High confidence
In forceHigh confidence
US 9,682,013Pharmaceutical Compositions Comprising Human Antibodies to PCSK9
In force
 · High confidence
In forceHigh confidence
US 10,927,435Compositions for the Treatment of Rheumatoid Arthritis and Methods of Using Same
In force
 · Medium confidence
In forceMedium confidence
US 9,574,004Methods for Treating or Preventing Asthma by Administering an IL-4R Antagonist
In force
 · High confidence
In forceHigh confidence
US 9,943,594Methods for the Treatment of Rheumatoid Arthritis
In force
 · High confidence
In forceHigh confidence
US 10,494,442Methods for Inhibiting Atherosclerosis by Administering an Inhibitor of PCSK9
In force
 · High confidence
In forceHigh confidence
US 10,995,150Methods for Inhibiting Atherosclerosis by Administering an ANTI-PCSK9 Antibody
In force
 · High confidence
In forceHigh confidence
US 10,059,771Methods for Treating Nasal Polyposis by Administering an IL-4R Antagonist
In force
 · High confidence
In forceHigh confidence
10 of 46 patents shown.
Pro members see all 46.
Pro members: see all 46 patents
Also on record, not counted in the 46: 6 patents in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

26 pending · 23 abandoned

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited